ZUMA-1 enrolled 111 patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL). Patients were required to have chemorefractory disease, defined as progressive or stable disease as best response to last line of therapy, or disease progression ≤12 months after autologous stem cell transplant. Manufacturing was successful for 110 patients, and 101 patients were treated. The pre-specified interim analysis was triggered when 51 patients with DLBCL had a minimum of three months of follow-up. At the time of interim analysis, 11 patients with PMBCL/TFL had been followed for three months. An additional 31 patients with one month of follow-up were included in the late breaker presentation.
"The vast majority of patients enrolled in ZUMA-1 are unable to undergo
autologous stem cell transplant due to chemorefractory disease. This
group has a dire need for more effective therapies," said
ZUMA-1 met the primary endpoint of objective response rate (ORR), p < 0.0001. Response rates by disease subtype are shown in the table below. Responses were observed across key subgroups, including 75 percent CR in patients who relapsed in ≤12 months after autologous stem cell transplant and 47 percent CR in patients refractory to second line or later chemotherapy. At the month three assessment, 39 percent of patients were in CR.
Best Overall Response in Patients with ≥3 Month Follow-up
|TFL / PMBCL||11||91%||73%|
In 93 patients with a minimum one month follow-up, the most common grade 3 or higher adverse events included neutropenia (63 percent), anemia (42 percent), leukopenia (40 percent), febrile neutropenia (29 percent), thrombocytopenia (26 percent), encephalopathy (19 percent), hypophosphatemia (17 percent), and decreased lymphocyte count (17 percent). Grade 3 or higher CRS and NE were observed in 13 percent and 29 percent of patients, respectively. Three patients died from treatment-emergent adverse events (hemophagocytic lymphohistiocytosis, cardiac arrest in the setting of CRS and pulmonary embolism). There were no cases of cerebral edema.
The primary analysis of ZUMA-1 will include a minimum of 6 months of
follow-up. Kite intends to seek regulatory approval of axicabtagene
ciloleucel in refractory aggressive
The late-breaker abstract (LBA-6), "KTE-C19 (anti-CD19 CAR T Cells)
Induces Complete Remissions in Patients with Refractory Diffuse Large
B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1," was
presented by Sattva S. Neelapu, M.D., Associate Professor, Deputy
Department Chair ad interim,
About axicabtagene ciloleucel
About Kite Pharma
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability and
timing of obtaining axicabtagene ciloleucel (KTE-C19) data, completing a
BLA submission with the
News Provided by Acquire Media